Katip Celebi University Ataturk Training and Research Hospital; Oncology
Izmir, Turkey
University hospital in İzmir
Basın Sitesi, Atatürk Eğitim ve Araştırma Hastanesi, 35360 Karabağlar/İzmir
About Katip Celebi University Ataturk Training and Research Hospital; Oncology
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
7
Izmir Ataturk Training and Research Hospital
2
Janssen Research & Development, LLC
2
Loxo Oncology, Inc.
1
Turkish Stroke Research and Clinical Trials Network
1
Clinical Trials at Katip Celebi University Ataturk Training and Research Hospital; Oncology
During the past decade, Katip Celebi University Ataturk Training and Research Hospital; Oncology conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 2 clinical trials were completed, i.e. on
average, 15.4% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 2 clinical trials were completed. i.e. 28.6%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
2017-08-25
2023-01-17
Completed
653
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
2018-01-06
2023-01-04
Completed
580
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
2018-03-23
2024-04-26
Recruiting
631
Detection of Muscle Loss in Acute Stroke Patients Who Need Enteral Nutrition (MASS)
2019-01-23
2021-11-30
Completed
125
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations
2019-08-01
2022-09-19
Completed
3,679
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
2020-02-17
2027-07-01
Active, not recruiting
250
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
2020-10-09
2027-03-18
Active, not recruiting
992
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Katip Celebi University Ataturk Training and Research Hospital; Oncology" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "Izmir Ataturk Training and Research Hospital" with 2 trials
sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored, "Loxo Oncology, Inc." with 1 trials sponsored and "Turkish Stroke Research and Clinical Trials Network"
with 1 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Katip Celebi University Ataturk Training and Research Hospital; Oncology"
#1 collaborator was "Abbott Nutrition" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Klinar CRO" with 1 trials as a collaborator and "Turkish Neurological Society" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 4 trials.
Clinical Trials Conditions at Katip Celebi University Ataturk Training and Research Hospital; Oncology
According to Clinical.Site data, the most researched conditions in "Katip Celebi University Ataturk Training and Research Hospital; Oncology" are
"Breast Cancer" (2 trials), "Urothelial Cancer" (2 trials), "Acute Ischemic Stroke" (1 trials), "Anxiety State" (1 trials) and "Costoclavicular and Infraclavicular Block for Patients Who Have Undergone Hand,Forearm and Arm Surgery" (1 trials). Many other conditions were trialed in "Katip Celebi University Ataturk Training and Research Hospital; Oncology" in a lesser frequency.
Clinical Trials Intervention Types at Katip Celebi University Ataturk Training and Research Hospital; Oncology
Most popular intervention types in "Katip Celebi University Ataturk Training and Research Hospital; Oncology" are "Drug" (9 trials), "Other" (3 trials) and "Device" (2 trials). Other intervention types were less common.
The name of intervention was led by "Giredestrant" (3 trials), "LHRH Agonist" (3 trials), "Paclitaxel" (3 trials), "Placebo" (3 trials) and "Atezolizumab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Katip Celebi University Ataturk Training and Research Hospital; Oncology
The vast majority of trials in "Katip Celebi University Ataturk Training and Research Hospital; Oncology" are
13 trials for "All" genders.
Clinical Trials Status at Katip Celebi University Ataturk Training and Research Hospital; Oncology
Currently, there are NaN active trials in "Katip Celebi University Ataturk Training and Research Hospital; Oncology".
undefined are not yet recruiting,
3 are recruiting,
4 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 6 completed trials in Katip Celebi University Ataturk Training and Research Hospital; Oncology,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Katip Celebi University Ataturk Training and Research Hospital; Oncology, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 8 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 1 trials that are defined as “Not Applicable".